Global Actinic Keratosis Treatment Market Report 2021

·5 min read

Dublin, Aug. 03, 2021 (GLOBE NEWSWIRE) -- The "Actinic Keratosis Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to's offering.

The actinic keratosis (AK) treatment market is anticipated to grow at a CAGR of about 4.5% during the forecast period 2021-2029.

Squamous cell carcinoma is a kind of cancer and early treatment reduces the risk to life. Threat related with untreated actinic keratosis is 20% higher than treated actinic keratosis. Hence, it is advisable to treat early to avoid progression of actinic keratosis and eventually squamous carcinoma.

Lack of Awareness is A Key Restraining Factor

Factors such as global warming, depletion of ozone layer, increasing number of cancer cases, chronic skin diseases and problems, sedentary lifestyle are the key factors that are rising the prevalence of this is condition and therefore, the market for AK treatment.

Whereas, lack of awareness related to actinic keratosis, is a major setback in the treatment of AK. Therefore, it becomes very essential to create awareness of AK and benefits of early treatment of AK so as to reduce the chances of progressing to a malignant stage.

Diagnosis Delayed Due To Pandemic

Due to COVID-19 there will be significant impact on global actinic keratosis market. Lockdowns, quarantines, social distancing, disturbed supply chain, constraints on travelling has been impacting routines and non essential services. People have been delaying visiting physicians and diagnostic centre unless it is for emergency.

Similarly, healthcare institutions as filled with covid 19 patients have not been encouraging other patients to visit hospitals for non critical cases. This has significantly delayed the diagnosis and therefore, the treatment. All the more in the case of AK initial symptoms are not very severe to rush for emergency diagnosis. This has delayed the diagnosis of AK.

North America Leading the AK treatment Market

North America is leading followed by Europe which is expected to grow comparatively at a higher rate. The reasons for growth of AK treatment market in North American and European actinic keratosis market are advanced healthcare infrastructure, awareness among people related to the disease and its treatment, high income, favourable regulatory framework and reimbursements.

Key Market Players

  • Sun Pharmaceutical Industries Ltd.

  • Nestle Skin Health Company

  • Biofrontera AG

  • Bausch Health Companies Inc.

  • Novartis AG

  • GlaxoSmithKline Plc.

  • Leo Pharma A/S

  • Almirall LLC

  • Cipher Pharmaceuticals Inc.

Key Topics Covered:

Chapter 1 Preface
1.1. Report Scope and Description
1.2. Research Methodology

Chapter 2 Executive Summary

Chapter 3 Market Overview
3.1 Introduction and Market Definition
3.2 Disease Primer and Epidemiology
3.2 Market Lineage Analysis
3.2.1 Parent market analysis
3.2.2 Ancillary market analysis
3.3 Penetration & Growth Prospect Mapping
3.4 Product Pipeline Analysis, by Stage
3.7 Regulatory Framework
3.8 Market Dynamics
3.8.1 Drivers High Prevalence of Actinic Keratosis and Subsequent Risk of Developing Malignancies
3.8.2 Restraints Non-adherence to Treatments
3.8.3 Market Opportunities Lucrative future for Light-based Treatments
3.9 Attractive Investment Proposition
3.10 Market Competition Assessment Key Players: Global Actinic Keratosis Market

Chapter 4 Actinic Keratosis Treatment Market: Segment Analysis, By Type of Therapy, 2019 - 2029 (US$ Million)
4.1 Definition and Scope
4.2 Therapy Type Market Share Analysis, 2019 & 2029
4.3 Segment Dashboard
4.4 Global Actinic Keratosis Market, by Therapy, 2019 to 2029
4.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
4.5.1 Topical
4.5.2 Surgery
4.5.3 Photodynamic therapy

Chapter 5 Actinic Keratosis Treatment Market: Segment Analysis, By Drug Class, 2019 - 2029 (US$ Million)
5.1 Definition and Scope
5.2 Drug Class Type Market Share Analysis, 2019 & 2029
5.3 Segment Dashboard
5.4 Global Actinic Keratosis Market, by Drug Class, 2019 to 2029
5.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
5.5.1 Nucleoside metabolic inhibitors
5.5.2 Nonsteroidal antiinflammatory drugs
5.5.3 Immune response modifiers
5.5.4 Photoenhancers

Chapter 6 Actinic Keratosis Treatment Market: Segment Analysis, By Medication, 2019 to 2029 (US$ Million)
6.1 Definition and Scope
6.2 Medication Type Market Share Analysis, 2019 & 2029
6.3 Segment Dashboard
6.4 Global Actinic Keratosis Market, by Medication, 2019 to 2029
6.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
6.5.1 fluorouracil cream market
6.5.2 imiquimod
6.5.3 Ingenol mebutate
6.5.4 Diclofenac

Chapter 7 Actinic Keratosis Treatment Market: Segment Analysis, By End use, 2019 to 2029 (US$ Million)
7.1 Definition and Scope
7.2 End use Type Market Share Analysis, 2019 & 2029
7.3 Segment Dashboard
7.4 Global Actinic Keratosis Market, by End use, 2019 to 2029
7.5 Market Size & Forecasts and Trend Analyses, 2019 to 2029
7.5.1 Hospitals
7.5.2 Private clinics
7.5.3 Homecare

Chapter 8 Actinic Keratosis Treatment Market: Regional Market Analysis, 2019 - 2029 (US$ Million)
8.1 Definition & Scope
8.2 Regional Market Share Analysis, 2019 & 2029
8.3 Regional Market Dashboard
8.4 Regional Market Snapshot
8.5 Regional Market Share Analysis 2019 to 2029
8.6 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
8.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2019 to 2029

For more information about this report visit

CONTACT: CONTACT: Laura Wood, Senior Press Manager For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting